IL2 and neoplasm: Additionally, the intratumoral injection of GD2 or epithelial cell adhesion molecule (EpCAM)-targeting IL-2 immunocytokines increased the anti-tumor effect and immune cell presence in neuroblastoma and melanoma in vivo compared to intravenous administration and unconjugated IL-2 [44,45,46,47].